Financial Performance - The company's revenue for the year ended December 31, 2023, was RMB 752.84 million, representing an increase of 28.50% compared to RMB 585.88 million in 2022[2]. - Gross profit for the same period was RMB 438.07 million, up 31.76% from RMB 332.49 million in the previous year[2]. - Net profit for the year was RMB 153.23 million, reflecting a growth of 14.50% from RMB 133.83 million in 2022[3]. - Basic and diluted earnings per share were both RMB 0.92, compared to RMB 0.79 and RMB 0.78 respectively in the prior year, marking increases of 16.46% and 17.95%[3]. - Total comprehensive income for the year was RMB 153.69 million, compared to RMB 135.72 million in 2022, indicating an increase of 13.23%[6]. Assets and Liabilities - Non-current assets increased to RMB 1,305.34 million as of December 31, 2023, from RMB 1,025.39 million in 2022, showing a growth of 27.38%[7]. - Current liabilities decreased to RMB 724.29 million in 2023 from RMB 801.94 million in 2022, a reduction of 9.66%[8]. - The company's total equity increased to RMB 1,678.38 million in 2023, up from RMB 1,554.10 million in the previous year, representing an increase of 8.00%[9]. - The company reported a significant increase in trade and other receivables, which rose to RMB 125.19 million in 2023 from RMB 79.53 million in 2022, an increase of 57.38%[7]. Revenue Breakdown - Revenue from cardiovascular and neurovascular devices amounted to RMB 608,231 thousand, while orthopedic and other devices generated RMB 3,145 thousand in 2023[15]. - The geographical breakdown of revenue shows that mainland China contributed RMB 549,503 thousand, up from RMB 437,344 thousand in 2022, indicating a growth of about 25.6%[17]. - Revenue from external customers in the cardiac intervention segment reached RMB 625,952,000, a 27.8% increase from RMB 489,704,000 in 2022[21]. - Total segment revenue for 2023 was RMB 801,562,000, up 27.1% from RMB 630,316,000 in 2022[23]. Expenses and Costs - Total operating expenses, including R&D costs, increased to RMB 125,850,000 in 2023 from RMB 99,634,000 in 2022, marking a 26.3% rise[27]. - Sales costs for the reporting period were approximately RMB 314.77 million, an increase of about 24.22% compared to RMB 253.40 million for the year ended December 31, 2022[67]. - Administrative expenses for the reporting period were approximately RMB 99.43 million, an increase of about 54.66% or RMB 35.14 million from approximately RMB 64.29 million for the year ended December 31, 2022[72]. - Research and development expenses for the reporting period were approximately RMB 179.31 million, an increase of about 27.22% or RMB 38.37 million from approximately RMB 140.94 million for the year ended December 31, 2022[73]. Dividends and Shareholder Returns - The board proposed a final dividend of RMB 0.27 per share for the year ended December 31, 2023, compared to RMB 0.24 per share in 2022, reflecting a 12.5% increase[49]. - The company’s cash dividends approved for the previous fiscal year amounted to RMB 40,320 thousand in 2023, down from RMB 43,680 thousand in 2022, a decrease of 7.5%[50]. Investments and Capital Expenditures - The company invested RMB 150 million in non-listed funds managed by Huai Ge Health Management, with RMB 125 million paid as of December 31, 2023[40]. - The company also invested RMB 50 million in another non-listed fund aimed at the healthcare sector, contributing RMB 10 million as of December 31, 2023[40]. - The group reported capital expenditures of approximately RMB 231.20 million for the reporting period, a decrease from RMB 301.06 million in 2022[90]. Research and Development - The company has a strong R&D capability and aims to leverage its comprehensive medical device registration certificates to gain a competitive advantage in the DRG/DIP payment system[51]. - The company plans to further develop its product pipeline and increase R&D investment, focusing on core product development and new product certification in 2024[65]. - The company has a strong R&D team with 334 registered patents and 208 pending patent applications as of December 31, 2023[54]. Corporate Governance and Compliance - The group has adopted a standard code of conduct for securities trading by directors and confirmed compliance during the reporting period[95]. - The Audit Committee, consisting of three members, has confirmed that the financial statements comply with applicable accounting principles and standards[97]. - The company has adhered to all corporate governance codes except for the separation of the roles of Chairman and CEO, which is held by Dr. Liang Dongke[96]. Future Plans and Strategic Initiatives - The company plans to utilize its R&D center to further enhance automation and scale production[65]. - The company is focused on investing in the medical device and biopharmaceutical sectors through various funds[87]. - The company has received approval from shareholders for the 2023 equity incentive plan, which includes the grant of 5,000,000 restricted shares to 17 incentive targets[59].

香 港 交易 及 結 算 所 有限 公 司 及 香港 聯 合 交 易 所有 限 公 司 對 本公 告 的 內 容概 不 負 責， 對 其 準 確 性或 完 整 性 亦不 發 表 任 何 聲明 ， 並 明 確 表示 ， 概 不 就因 本 公 告全 部 或 任 何 部分 內 容 而 產生 或 因 倚 賴 該等 內 容 而 引 致之 任 何 損 失承 擔任何責任。 Shanghai Kindly Medical Instruments Co., Ltd. * 上 海 康 德 萊 醫 療 器 械 股 份 有 限 公 司 （ 於中華人民共和國註冊成立的股份有限公司 ） （股份代號：1501） 有關2022年報的補充公告 茲提述上海康德萊醫療器械股份有限公司於2023年4月13日刊發的年度報告 （「2022 年 報」）。 除 非 文 義 另 有 所 指 ， 否 則 本 公 告 所 用 詞 彙 與 2022 年 報 所 界 定 者 具 有 相同 涵 義 。 本 公 告 提供 年 報 的 補 充 資 料， 並 應 與 2022 年 報 一 併閱 讀。 有關股份激勵計劃及根據股份激勵計劃授出獎勵的詳情（ 載於2022年報第32 ...

Financial Performance - For the six months ended June 30, 2023, the company's revenue was approximately RMB 339.76 million, an increase of 50.86% compared to RMB 225.22 million for the same period in 2022[5]. - The gross profit for the reporting period was approximately RMB 200.35 million, with a gross margin increase from 55.07% to 58.97%[6]. - The profit for the period was approximately RMB 80.51 million, representing a 60.61% increase from RMB 50.13 million in the previous year[6]. - Basic earnings per share for the reporting period were RMB 0.48, up 54.84% from RMB 0.31 in the same period last year[6]. - Other income for the reporting period was approximately RMB 22.79 million, a 4.51% increase from RMB 21.81 million for the same period last year[20]. - The total comprehensive income for the period was RMB 81,554,000, up from RMB 50,957,000 in the same period last year[74]. - The company reported a profit of RMB 80,502 thousand for the six months ended June 30, 2023, compared to RMB 50,841 thousand for the same period in 2022, marking a growth of 58.5%[78]. - The company reported a net cash outflow from financing activities of RMB 19,177,000, compared to an outflow of RMB 19,804,000 in the same period last year[79]. Revenue Breakdown - Revenue from interventional medical devices was approximately RMB 302.26 million, up from RMB 192.44 million for the same period last year, representing an increase of about RMB 109.82 million[17]. - Revenue from cardiovascular devices reached RMB 282,085,000, up 53.3% from RMB 184,171,000 year-on-year[83]. - Revenue from external customers in mainland China was RMB 267,569,000, a 47.5% increase compared to RMB 181,503,000 in the previous year[85]. - Revenue for the same period was RMB 339,764,000, up 50.8% from RMB 225,217,000 year-on-year[72]. Research and Development - Research and development expenses totaled approximately RMB 86.53 million, accounting for about 25.47% of total revenue, compared to 23.71% for the same period last year[24]. - Research and development costs for the period amounted to RMB 86,537,000, which is a 62.0% increase from RMB 53,391,000 in the previous year[91]. - The company received government subsidies totaling RMB 5,913,000, compared to RMB 2,686,000 in the prior period, indicating a significant increase in support for R&D projects[89]. - The company plans to further develop its product pipeline and increase R&D investment in the second half of 2023[14]. Market Position and Strategy - The company is a leading manufacturer of cardiovascular interventional devices in China, with a complete industry chain from design to sterilization[7]. - The increase in revenue was primarily driven by growing market demand and an increase in the number of new customers[5]. - The company plans to leverage its strong brand marketing system and R&D capabilities to gain a larger market share as procurement scopes expand[8]. - The company is exploring market expansion opportunities, particularly in the medical device sector, to enhance its competitive position[1][58]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by the end of 2024[138]. Shareholder Information - The company’s board of directors consists of two executive directors, four non-executive directors, and three independent non-executive directors, ensuring strong governance and independence[41]. - The company has disclosed no additional interests or short positions held by directors or senior management as of June 30, 2023[49]. - Major shareholders include Mr. Wang Kai and Ms. Zhao Wei, each holding 14.19% of H shares, representing approximately 8.80% of total shares[1][57]. - The company continues to maintain transparency regarding its shareholder structure and compliance with regulatory requirements[50]. Capital Expenditures and Investments - Capital expenditures for the period amounted to approximately RMB 148.63 million, compared to RMB 103.99 million for the same period in 2022, representing an increase of 43%[38]. - The group has utilized approximately RMB 647.41 million of the net proceeds from the global offering, with planned uses including the construction of a R&D center and expansion of production facilities[30]. - The group has significant investments in various partnerships, with a total investment cost of RMB 125 million and a fair value of RMB 159.974 million as of June 30, 2023[34]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of RMB 200 million allocated for this purpose[138]. Cash Flow and Liquidity - As of June 30, 2023, the group's cash and cash equivalents were approximately RMB 458.22 million, down from RMB 518.27 million as of December 31, 2022, with net cash flow from operating activities of approximately RMB 66.19 million for the six months ended June 30, 2023[27]. - The total current assets as of June 30, 2023, were approximately RMB 728.20 million, while total current liabilities were approximately RMB 306.35 million, resulting in a current ratio of about 2.38[27]. - The company’s cash and cash equivalents included bank deposits of RMB 458,164 thousand as of June 30, 2023, compared to RMB 518,245 thousand as of December 31, 2022[112]. - Cash and cash equivalents decreased to RMB 458,217 thousand from RMB 518,266 thousand, a decline of 11.6%[75]. Share Incentive Plan - The board approved a share incentive plan to grant up to 5,000,000 restricted shares to no more than 100 employees, with 2,500,000 shares allocated to Dr. Liang Dongke and the incentive platform[60]. - The total number of restricted shares granted to Dr. Liang Dongke is 3,234,300, with no cancellations or forfeitures reported during the period[62]. - The company plans to seek shareholder approval for amendments to the performance targets of the share incentive plan, extending the review period to December 31, 2023[61]. - The company did not grant any restricted shares during the six months ended June 30, 2023, compared to 341,900 shares granted in the same period of 2022, indicating a complete halt in new grants[106].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 Shanghai Kindly Medical Instruments Co., Ltd.* 上海康德萊醫療器械股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1501） 截 至2023年6月30日止六個月期間 中期業績公告 | --- | --- | --- | --- | |-----------------------------|---------------|----------------|--------| | | | | | | | | | | | | 截 至 6 月 30 | 日止六個月期間 | | | | 2023 年 | 2022 年 | 變 動 | | | 人民幣千元 | 人民幣千元 | | | | | | | | 收 入 | 339,764 | 2 ...

Financial Performance - The company's revenue for the year ended December 31, 2022, reached approximately RMB 585.88 million, an increase of about 26.08% compared to RMB 464.68 million for the year ended December 31, 2021[5]. - Revenue from the sale of interventional medical devices was approximately RMB 505.48 million, representing a growth of about 15.89% from RMB 436.16 million in the previous year[5]. - The company's profit for the reporting period was approximately RMB 133.83 million, a decrease of about 4.7% from RMB 140.45 million in the previous year[5]. - The gross profit for 2022 was RMB 332.49 million, resulting in a gross margin of 56.7%, down from 59.3% in 2021[11]. - The net profit for the year was RMB 133.83 million, with a net profit margin of 22.8%, a decrease from 30.2% in 2021[11]. - The basic and diluted earnings per share for the reporting period were RMB 0.79 and RMB 0.78, respectively, compared to RMB 0.86 for both in the previous year[5]. - Other income decreased by approximately 32.15% to RMB 34.04 million from RMB 50.17 million in the previous year[30]. - Distribution costs increased by approximately 87.85% to RMB 56.39 million, accounting for about 9.63% of total revenue, up from 6.46% in the previous year[32]. - Administrative expenses for the reporting period were approximately RMB 642.9 million, an increase from RMB 490.5 million for the year ended December 31, 2021, primarily due to salary and compensation increases from business expansion[33]. - Research and development expenses amounted to approximately RMB 1,409.4 million, with RMB 413.1 million capitalized as intangible assets and RMB 996.3 million deducted from profit and loss, representing a 28.35% increase from RMB 1,098.1 million for the year ended December 31, 2021[34]. Distribution Network and Market Presence - The company has a distribution network covering 2,317 hospitals in China, including 908 tertiary hospitals, and has 207 overseas customers across 58 countries and regions[6][8]. - The company expanded its distribution network to cover 2,317 hospitals in China, including 908 top-tier hospitals, and has 207 overseas clients across 58 countries[17]. - The largest customer accounted for 8.29% of total sales, while the top five customers collectively represented 22.38% of total sales[61]. - The largest supplier accounted for 8.14% of total purchases, with the top five suppliers making up 27.95% of total purchases[61]. Research and Development - As of December 31, 2022, the company held 260 registered patents, 184 pending patent applications, and 5 registered software copyrights[7]. - The company obtained 9 new product registration certificates during the reporting period, including 6 Class III medical device registrations and 3 Class II registrations[7]. - The company has obtained 6 Class III medical device registrations and 3 Class II registrations from the National Medical Products Administration in 2022, totaling 31 Class III and 23 Class II registrations by year-end[15]. - The company applied for 91 new patents during the reporting period, emphasizing its commitment to technological innovation and product competitiveness[163]. Future Plans and Investments - The company plans to enhance its product pipeline and increase R&D investment to maintain its leading position in the interventional medical device industry in 2023[5]. - The company aims to leverage its new R&D center in Shanghai and a new factory in Zhuhai to improve automation and scale production[5]. - The company plans to utilize RMB 156.33 million for the construction of the Shandong Yingtai Innovation Medical Devices Industrial Park, with an expected completion date in June 2024[43]. - The company has committed to invest RMB 50 million in the Chengdu Huige Fund, focusing on early-stage or growth-stage companies in the medical and biotechnology sectors[25]. Corporate Governance - The board of directors is committed to establishing good corporate governance standards to protect shareholder interests and enhance transparency and accountability[111]. - The company has a governance structure consisting of the general meeting of shareholders, board of directors, supervisory board, and management, ensuring clear responsibilities and coordination among these entities[112]. - The board has established an audit committee, remuneration committee, and nomination committee to oversee various responsibilities[115]. - The company has complied with the corporate governance code and has appointed more than the minimum required number of independent non-executive directors since its listing[119]. - The board believes that the company's structure provides adequate checks and balances to enhance risk management procedures[143]. Environmental, Social, and Governance (ESG) Initiatives - The company’s ESG report for 2022 highlights key issues such as product health and safety, supply chain management, and customer privacy[161]. - The company has established an ESG governance structure to oversee environmental and social matters, ensuring sustainable development[165]. - The company emphasizes the importance of timely and accurate information disclosure to enhance investor relations and transparency[155]. - The company is committed to energy conservation and resource-saving practices to contribute to an environmentally friendly society[164]. - The company has implemented strict quality control measures throughout the supply chain to ensure high-quality products for users[162]. Employee and Workforce Management - The total number of full-time employees at the end of the reporting period was 1,632, an increase from 1,189 in 2021, indicating a growth in workforce[199]. - The employee turnover rate for male employees in 2022 was 33.70%, while for female employees it was 33.00%[200]. - The company emphasizes the importance of employee rights and provides competitive salaries and benefits to foster a supportive work environment[199]. - The company has established a comprehensive training system to foster a motivated workforce[163]. Financial Position and Capital Management - The total assets of the company as of December 31, 2022, were RMB 1,827.33 million, compared to RMB 1,621.55 million in 2021[12]. - The debt-to-capital ratio as of December 31, 2022, was 3.14%, up from 0.93% in 2021, with bank loans amounting to approximately RMB 326.8 million[38]. - Total equity attributable to equity shareholders was approximately RMB 15,120.2 million as of December 31, 2022, compared to RMB 13,954.7 million as of December 31, 2021[39]. - The company has a total of RMB 162.08 million in authorized but uncontracted capital commitments as of December 31, 2022[51]. Shareholder Information - The board proposed a final dividend of RMB 0.24 per share for the year ended December 31, 2022, compared to RMB 0.26 per share in 2021[40]. - The total number of shares outstanding as of December 31, 2022, is 168,000,000, consisting of 63,786,608 domestic shares and 104,213,392 H shares[81]. - The company has received shareholder approval to change its name to "Shanghai INT Medical Instruments Co., Ltd." to strengthen brand recognition and align with future strategic development[24]. Compliance and Risk Management - The company has established policies and procedures to identify, assess, and control risks that may hinder business operations[143]. - The board is responsible for the risk management and internal control systems, which are reviewed for effectiveness at least annually, with the audit committee assisting in oversight[143]. - The company has mechanisms in place to ensure that directors can seek independent professional advice when necessary, with costs covered by the company[121]. Community Engagement and Social Responsibility - The company provided suitable positions for 7 disabled individuals from the surrounding community, highlighting its commitment to social responsibility[163]. - The group donated RMB 100,000 to the Shanghai Jiading District Education Reward Foundation and RMB 30,000 for charity activities, along with over 220,000 self-produced masks to medical institutions and government agencies[101].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內 容 概 不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致之 任 何 損 失 承 擔 任 何 責 任。 Shanghai Kindly Medical Instruments Co., Ltd.* 上海康德萊醫療器械股份有限公司 （於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司） （股 份 代 號：1501） 截 至2022年12月31日止年度 全年業績公告 財務概要 | --- | --- | --- | --- | |-----------------------------|------------|------------|--------| | | 2022 年 | 2021 年 | 變 動 | | | 人民幣千元 | 人民幣千元 | | | | | | | | 收 入 | 585,883 | 464,675 | 26.08% | | 毛 利 | 332,486 | 275,745 | 20.58% ...

Shanghai Kindly Medical Instruments Co., Ltd. 上海康德萊醫療器械股份有限公司 Interim Report 中期報告 2020 上海康德萊醫療器械股份有限公司 Shanghai Kindly Medical Instruments Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） Stock Code : 1501 (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號：1501 創新 服務健康 品質 鑄就非凡 * 僅供識別 中期報告 2020 | --- | --- | --- | --- | --- | |-------|----------------------------------------------------------|-------|-------|-------| | | | | | | | | | | | | | | 目 錄 上海康德萊醫療器械股份有限公司 二零二零年中期報告 | ...